SLNSW-Safety analysis of two different regimens of urac...-TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

Full title: Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

Author/creator: Tsuchiya, Takashi, Sadahiro, Sotaro, Sasaki, Kazuaki, Kondo, Ken, Katsumata, Kenji, Nishimura, Genichi, Kakeji, Yoshihiro, Baba, Hideo, Morita, Takayuki, Koda, Keiji, Sato, Seiji, Matsuoka, Junji, Yamaguchi, Yoshiyuki, Usuki, Hisashi, Hamada, Chikuma, Kodaira, Susumu, Saji, Shigetoyo.

Call Numbers:

Record Identifier: TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

Language: English

Formats: Articles

Publishers: Berlin/Heidelberg: Springer Berlin Heidelberg

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

    Record identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

    Share

    Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

    Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

    Full title

    Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

    Author / Creator

    Tsuchiya, Takashi ; Sadahiro, Sotaro ; Sasaki, Kazuaki ; Kondo, Ken ; Katsumata, Kenji ; Nishimura, Genichi ; Kakeji, Yoshihiro ; Baba, Hideo ; Morita, Takayuki ; Koda, Keiji ; Sato, Seiji ; Matsuoka, Junji ; Yamaguchi, Yoshiyuki ; Usuki, Hisashi ; Hamada, Chikuma ; Kodaira, Susumu ; Saji, Shigetoyo

    Publisher

    Berlin/Heidelberg: Springer Berlin Heidelberg

    Journal title

    Cancer chemotherapy and pharmacology, 2014, Vol.73 (6), p.1253-1261

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adjuvant chemotherapy Adjuvant treatment Aged Aged, 80 and over Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Cancer Cancer Research Chemotherapy, Adjuvant Clinical trials Colon cancer Colonic Neoplasms - drug therapy Colonic Neoplasms - pathology Colonic Neoplasms - surgery Drug Administration Schedule Female Gastroenterology. Liver. Pancreas. Abdomen Humans Leucovorin Leucovorin - administration & dosage Male Medical sciences Medicine Medicine & Public Health Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Staging Oncology Original Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Product development Pyrimidines Risk Factors Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tegafur - administration & dosage Tegafur - adverse effects Treatment duration Tumors Uracil - administration & dosage Uracil - adverse effects Uracil–tegafur (UFT)

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4032639

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    About resource >

    View in old catalogue

    Connecting people and collections